Phase 1 N=29 Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions
Adverse Drug Interactions
Primary: Midazolam Clearance (Pharmacokinetic Measure of Cytochrome P450 3A4 Activity) — 604; 552; 541; 156 ng*min/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=19 Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction
HIV
Primary: AUC — 94.17; 34.67; 100.44; 32.58 h*microgram/mL
Early Phase 1 N=22 Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients
Interaction, Adverse Herb-Drug · Diabetes Mellitus, Type 2
Primary: Metformin AUC — 59.6; 54.5; 57.3 mcg*hr/mL
Phase 1 N=22 Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs
Drug-Interactions
Primary: Losartan Area Under the Curve (AUC) in Plasma — 164; 185; 289 h*ng/mL
N/A N=19 The Adverse Drug Reaction (ADRe) Profile for Polypharmacy
Polypharmacy
Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants
Phase 4 N=28 Drug-Drug Interaction of Cardizem LA (Diltiazem Hydrochloride) on Pitavastatin
Healthy
Primary: NK-104 AUC — 208.92 ng * h/mL
Early Phase 1 N=8 Assessing the Pharmacokinetics and Drug Interaction Liability of Kratom, an Opioid-like Natural Product
Interaction Drug Food
Primary: Midazolam Area Under the Concentration vs. Time Curve (AUC) — 58.3; 80.8 nM * hr
Phase 1 N=11 Prescription Medication Interactions
Opioid Use · Sedative Use
Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001
N/A N=348 Emergency Department (ED) Drug Interaction in Emergency Department Patients
Drug Interactions
Primary: Difference in Clinically Significant Visual Analogue Scale for Pain and Nausea Change Between CYP2D6 Users and Non-users — 7.4; 10.9; -14.0 millimeters
Phase 1 N=24 Drug-Drug Interaction Between Colchicine and Verapamil ER
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2,968.42; 3,850.63 pg/mL
Phase 1 N=30 Transporter Cocktail Mutual Interaction
Healthy
Primary: Area Under the Curve of Digoxin From 0 to Last Quantifiable Data Point (AUC 0-tz) — 11.549; 11.981 nanomole hour per liter (nmol·h/L)
N/A N=10 The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity
Drug-Drug Interaction · Healthy Volunteers
Primary: Lovastatin AUC in the Presence of Fluoxetine — 170; 180 nmol*hr/L — p=>0.05
Phase 4 N=47 Drug Interactions of Echinacea, Ginseng, and Ginkgo Biloba Taken With Lopinavir/Ritonavir in Healthy Volunteers
Healthy
Primary: Lopinavir Pharmacokinetics When Administered Alone and in Combination With Three Different Herbal Supplements: Ginkgo Biloba, Panax Ginsing, and Echinacea Purpurea…
Phase 1 N=24 Drug-Drug Interaction Between Colchicine and Ritonavir
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 1,869.50; 4,993.06 pg/mL
Phase 1 N=24 Drug-Drug Interaction Study Between Colchicine and Diltiazem ER
Healthy; Adult; Volunteer; Colchicine; Pharmacokinetics; Diltiazem; Cytochrome p450 3A4; P-glycoprotein
Primary: Maximum Plasma Concentration (Cmax) — 2,172.32; 2,802.90 pg/mL
N/A N=125 Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAH
Pulmonary Arterial Hypertension
Primary: Characterisation of Medication Levels — 5.54; 2.18; 1.81; 1.53 MOM
Phase 2 N=129 Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents
Healthy
Primary: Area Under Concentration-time Curve From 0 to Last Measureable Concentration (AUC0-t) Atorvastatin Acid (Lomitapide 10 mg) — 110.97 Ratio
Phase 4 N=28 Drug-Drug Interaction of Darunavir/Ritonavir on Pitavastatin
Healthy
Primary: NK-104 AUC — 192.00 ng * h/mL
Phase 1 N=13 Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin
Healthy
Primary: Area Under the Concentration-time Curve of Midazolam in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 19.0; 23.5; 16.0 nanogram…
Phase 1 N=24 Drug-Drug Interaction Study of Colchicine and Clarithromycin
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2.84; 8.44 ng/mL
N/A N=18 Do Furanocoumarins Mediate the Fexofenadine-grapefruit Juice Interaction?
Food-drug Interaction
Primary: Primary Pharmacokinetic Measure: Area Under the Curve (AUC) — 4.2; 4.2; 4.2; 3.2 micromolar*hr — p=0.78
Phase 1 N=11 Doravirine, Rifapentine and Isoniazid Interaction
Latent Tuberculosis · Human Immunodeficiency Virus · Rifamycins Causing Adverse Effects in Therapeutic Use
Primary: Doravirine Maximum Concentration (Cmax) — 1.7; 1.3 ug/mL
Phase 1 N=16 Drug Drug Interaction of BI 201335 and Tenofovir
HIV Infections
Primary: Steady-state Pharmacokinetics of AUC0-24 of Tenofovir on Day 7 and on Day 15 — 2700; 3290 ng*h/mL
Phase 1 N=24 Drug-Drug Interaction Study Between Colchicine and Ketoconazole
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2,779.08; 5,266.92 pg/mL
Phase 1 N=42 SSP-002358 Drug Interaction Study With Omeprazole
Healthy
Primary: Maximum Plasma Concentration (Cmax) for SSP-002358 — 3.89; 4.12 ng/ml
Phase 4 N=24 Drug-Drug Interaction of Lopinavir/Ritonavir on Pitavastatin
Healthy Volunteers
Primary: Area Under the Curve From Time 0 to Tau (AUC 0-τ) — 113.92 ng•h/mL
Phase 1 N=24 Drug-Food Interaction Study of Seville Orange Juice and Colchicine
Healthy
Primary: Maximum Plasma Concentration (Cmax) of Colchicine — 2,328.44; 1,668.33 pg/mL
Phase 1 N=12 Ph1 Marinol Interaction Study - Part 2 - 1
Marijuana Dependence
Primary: Number of Participants That Experience Cardiovascular Effects of Smoked Marijuana or Has Any Other Combination Side Effects. — 6; 6 participants
Phase 1 N=20 Interaction of BI 691751 With Itraconazole
Healthy
Primary: AUC0-tz (Area Under the Concentration-time Curve of BI 691751 in Plasma and Whole Blood Over the Time Interval From 0 up to the Last Quantifiable Concentration) — 2830…
Phase 1 N=30 Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz
Healthy
Primary: Maximum Plasma Concentration (Cmax) of Efavirenz — 2,461.58; 2,384.79 ng/mL